Rankings
▼
Calendar
TARS FY 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
-32.4% YoY
Gross Profit
$16M
90.9% margin
Operating Income
-$143M
-820.5% margin
Net Income
-$136M
-778.9% margin
EPS (Diluted)
$-4.62
Cash Flow
Operating Cash Flow
-$117M
Free Cash Flow
-$123M
Stock-Based Comp.
$20M
Balance Sheet
Total Assets
$265M
Total Liabilities
$69M
Stockholders' Equity
$197M
Cash & Equivalents
$225M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$17M
$26M
-32.4%
Gross Profit
$16M
$25M
-36.2%
Operating Income
-$143M
-$63M
-128.3%
Net Income
-$136M
-$62M
-118.9%
← Q4 2022
All Quarters
Q1 2023 →